Results 131 to 140 of about 129,468 (342)

Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease

iMetaOmics, EarlyView.
This narrative review uniquely addresses how gut microbiota‐derived metabolites mediate overlapping pathologies of insulin resistance, neuroinflammation, and amyloidogenesis in type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), proposing a framework for dual therapeutic targeting.
Guangyi Xu, Yu An, Yage Du, Zhaoming Cao, Jie Zheng, Jingya Wang, Tingyi Li, Xingen Lei, Yanhui Lu   +8 more
wiley   +1 more source

Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes.

Journal of the American College of Cardiology, 2021
X. Rosselló, S. Raposeiras-Roubín, B. Oliva, F. Sánchez-Cabo, J. M. García-Ruíz, F. Caimari, J. Mendiguren, E. Lara-Pezzi, Héctor Bueno, L. Fernández-Friera, A. Fernández-Ortiz, J. Sanz, B. Ibáñez, V. Fuster   +13 more
semanticscholar   +1 more source

Temporal response patterns of human gut microbiota to dietary fiber

iMeta, EarlyView.
In this study, 19 overweight participants, with or without type 2 diabetes mellitus, underwent 14 days of normal‐diet observation followed by 14 days of dietary fiber intervention. Fecal samples and continuous glucose monitoring data were collected daily throughout the 28‐day period.
Xiaotong Lin, Chaoxun Wang, Biao Liu, Yin Zhu, Rui Zhai, Chenhong Zhang   +5 more
wiley   +1 more source

An Analysis of the Assessment of Glycated Hemoglobin Using A1cNow+™ Point-of-Care Device Compared to Central Laboratory Testing—an Important Addition to Pharmacist-Managed Diabetes Programs? [PDF]

, 2008
Alan W. Carter
openalex   +1 more source

Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects

The Journal of Clinical Pharmacology, EarlyView.
Abstract Recognition of benefits and adverse effects of therapies in earlier clinical trial phases could improve the safety, efficiency, and cost of clinical trials. Using four clinical trials representing a diverse set of diseases and drug classes (EXSCEL: exenatide/GLP‐1 RA, SUGAR‐DM‐HF: empagliflozin/SGLT2i, PRADA: epirubicin/anthracycline, and ...
Jessica Chadwick, Colin Berry, Meredith A. Carpenter, Geeta Gulati, Siri Lagethon Heck, Michael A. Hinterberg, Rury R. Holman, Matthew M.Y. Lee, Torbjørn Omland, Clare Paterson, Mark C. Petrie, Naveed Sattar, Svati H. Shah, Sama Shrestha, Harald Sourij, Emma V Troth, Victoria Vinje, Stephen A. Williams   +17 more
wiley   +1 more source

Assessment of Glycated Hemoglobin Using A1CNow™ Point-of-Care Device as Compared to Central Laboratory Testing [PDF]

, 2008
Justin R. Arrendale, Sonia E. Cherian, Issam Zineh, Mark J. Chirico, James R. Taylor   +4 more
openalex   +1 more source

Prognostic Impact of Unplanned Total Pancreatectomy in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background This study evaluated the clinical significance of an unplanned total pancreatectomy (TP) by comparing surgical outcomes of planned and unplanned TP for pancreatic ductal adenocarcinoma (PDAC). Methods Forty‐two patients who underwent TP for PDAC between 2009 and 2020 at the Kindai University Hospital were retrospectively analyzed ...
Dongha Lee, Keiko Kamei, Chihoko Nobori, Yuta Yoshida, Takaaki Murase, Atsushi Takebe, Takuya Nakai, Mamoru Takenaka, Takaaki Chikugo, Ippei Matsumoto   +9 more
wiley   +1 more source

A Risk Analysis for Ischemic Necrosis of the Remnant Stomach After Distal Pancreatectomy in Patients With Previous Distal Gastrectomy: A Multicenter Retrospective Survey by the Japanese Society of Pancreatic Surgery

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background/Purpose The remnant stomach after distal gastrectomy (DG) which receives its blood supply mainly from the splenic artery (SPA), is at high risk for gastric ischemia following distal pancreatectomy (DP). We investigated the risk factors for ischemic necrosis of the remnant stomach (INS) during or after DP in DG patients.
Takashi Kishi, Yoshitsugu Tajima, Hikota Hayashi, Yasunari Kawabata, Kenichiro Uemura, Minako Nagai, Kohei Nishio, Kengo Fukuzawa, Shintaro Yagi, Masaaki Hidaka   +9 more
wiley   +1 more source

Salivary advanced glycated end products, their receptors, and aMMP‐8 in periodontitis patients with varying glycemic levels: A cross‐sectional study

Journal of Periodontology, EarlyView.
Abstract Background Advanced glycation end products (AGE) and their receptors (RAGE) have been implicated in developing periodontal complications in diabetic patients. This study aimed to identify salivary AGE, RAGE, soluble RAGE (sRAGE), and active‐matrix metalloproteinase‐8 (aMMP‐8) levels at varying glycemic levels in periodontitis patients ...
Julie Toby Thomas, Betsy Joseph, Sajit Varghese, Baiju Kamalasanan Vijayakumari, Timo Sorsa, Matti Mauramo, Sukumaran Anil, Tuomas Waltimo   +7 more
wiley   +1 more source

Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults [PDF]

, 2010
Giuseppe Lippi, Camilla Mattiuzzi, Giovanni Targher   +2 more
openalex   +1 more source